

P&T Committee Review Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Review
Location:	628 NORTH 4TH STREET, ROOM 118 BATON ROUGE, LOUISIANA 70802
Date:	May 9 th , 2025
Members Present:	<ul style="list-style-type: none"> ▪ Dr. Mary Raven ▪ Pamela G. Reed ▪ Dr. Mairus McFarland ▪ Dr. Vanessa De La Cruz ▪ Shantel Hebert-Magee
LDH Staff Present:	<ul style="list-style-type: none"> ▪ Katrina Johnson ▪ Sue Fontenot, RPh ▪ Haley Williams ▪ Melwyn Wendt
Contractors Present:	<ul style="list-style-type: none"> ▪ Hind Douiki, PharmD, Prime Therapeutics State Government Solutions
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Ms. Wendt announced that the Chairman and Vice-Chairman were unable to attend the meeting. Dr. Vanessa De La Cruz volunteered to Chair the meeting. She called the meeting to order at or around 9:37 am CT.

Parliamentary Business

- A. **Introduction of Members/Roll Call.** Dr. De La Cruz asked P&T Committee members, LDH staff, and Prime staff to introduce themselves.
- B. **Approval of October 30, 2024 Meeting Minutes.** Dr. De La Cruz indicated the members cannot vote on approval of the Minutes due to not having quorum.

Ethics

Ms. Williams presented the code of governmental ethics for the P&T committee members. She indicated they set forth objective standards of conduct to protect public confidence in the integrity of government by ensuring public servants remain independent and impartial, decisions and policy are made in the proper channel, and public positions are not used for private gain.

Reports

Ms. Wendt informed the P&T Committee members that LA currently participates in the TOP\$ pool to maximize supplemental rebates. She also noted that in the past they had a separate contract with Asegua on a Hepatitis C Agent, Ledipasvir/Sofosbuvir (generic EPCLUSA). They will have completed the 6th year at the end of June and will start one more year with generic EPCLUSA being the preferred agent for the next fiscal year.

Public Testimony

Ms. Douiki asked that any member of the public who wished to provide testimony to wait until their therapeutic class is reviewed and then raise their hand once the Chair asks if there is any public testimony. Once the testimony is started, a timer will be placed on the screen. She kindly asked that any speaker who has signed up to provide testimony and their drug is preferred, to give their time back.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Ms. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. She also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Edward Mendez	Amgen	Repatha
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Acne Agents, Topical

Recommendations for the PDL are:

- CLINDAMYCIN / BENZOYL PEROXIDE (BENZACLIN) (TOPICAL)
- CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)
- CLINDAMYCIN PHOSPHATE GEL (TOPICAL)
- CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)
- CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL)

- CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)
- ERYTHROMYCIN GEL (TOPICAL)
- ERYTHROMYCIN SOLUTION (TOPICAL)
- TRETINOIN CREAM (TOPICAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Long

Recommendations for the PDL are:

- BUPRENORPHINE (AG) (TRANSDERM)
- BUPRENORPHINE (TRANSDERM)
- FENTANYL (TRANSDERM)
- MORPHINE ER TABLET (ORAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Short

Recommendations for the PDL are:

- APAP / CODEINE ELIXIR (ORAL)
- APAP / CODEINE TABLET (ORAL)
- HYDROCODONE / APAP SOLUTION (ORAL)
- HYDROCODONE / APAP TABLET (ORAL)
- HYDROMORPHONE TABLET (ORAL)
- MORPHINE DISP SYRIN (ORAL)
- MORPHINE IR TABLET (ORAL)
- OXYCODONE / APAP TABLET (ORAL)
- OXYCODONE TABLET (ORAL)
- TRAMADOL (ORAL)
- TRAMADOL / APAP (ORAL)

There were no further discussions made by the committee about this class.

Androgenic Agents

Recommendations for the PDL are:

- TESTOSTERONE GEL PACKET (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PUMP (ANDROGEL) (TRANSDERM)

There were no further discussions made by the committee about this class.

Angiotensin Modulator Combinations

Recommendations for the PDL are:

- AMLODIPINE / BENAZEPRIL (ORAL)
- AMLODIPINE / OLMESARTAN (AG) (ORAL)

- AMLODIPINE / OLMESARTAN (ORAL)
- AMLODIPINE / VALSARTAN (ORAL)

There were no further discussions made by the committee about this class.

Angiotensin Modulators

Recommendations for the PDL are:

- BENAZEPRIL (ORAL)
- BENAZEPRIL HCTZ (ORAL)
- ENALAPRIL (ORAL)
- ENALAPRIL HCTZ (ORAL)
- ENALAPRIL SOLUTION (AG) (ORAL)
- ENALAPRIL SOLUTION (ORAL)
- ENTRESTO (ORAL)
- FOSINOPRIL (ORAL)
- FOSINOPRIL HCTZ (ORAL)
- IRBESARTAN (ORAL)
- IRBESARTAN HCTZ (ORAL)
- LISINOPRIL (ORAL)
- LISINOPRIL HCTZ (ORAL)
- LOSARTAN (ORAL)
- LOSARTAN HCTZ (ORAL)
- OLMESARTAN (AG) (ORAL)
- OLMESARTAN (ORAL)
- OLMESARTAN HCTZ (AG) (ORAL)
- OLMESARTAN HCTZ (ORAL)
- RAMIPRIL (ORAL)
- VALSARTAN (ORAL)
- VALSARTAN HCTZ (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, GI

Recommendations for the PDL:

- METRONIDAZOLE TABLET (ORAL)
- NEOMYCIN (ORAL)
- TINIDAZOLE (ORAL)
- VANCOMYCIN CAPSULE (AG) (ORAL)
- VANCOMYCIN CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, Inhaled

Recommendations for the PDL:

- TOBI PODHALER (INHALATION)
- TOBRAMYCIN (TOBI) (INHALATION)

There were no further discussions made by the committee about this class.

Antibiotics, Topical

Recommendations for the PDL are:

- MUPIROCIN OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Antibiotics, Vaginal

Recommendations for the PDL are:

- CLINDAMYCIN (VAGINAL)
- METRONIDAZOLE (VAGINAL)
- NUVESSA (VAGINAL)

There were no further discussions made by the committee about this class.

Anticoagulants

Recommendations for the PDL are:

- DABIGATRAN (ORAL)
- ELIQUIS (ORAL)
- ELIQUIS DOSE PACK (ORAL)
- ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANE.)
- ENOXAPARIN SODIUM VIAL (SUBCUTANE.)
- ENOXAPARIN SYRINGE (AG) (SUBCUTANE.)
- ENOXAPARIN SYRINGE (SUBCUTANE.)
- RIVAROXABAN TABLET (XARELTO) (ORAL)
- WARFARIN (ORAL)
- XARELTO DOSE PACK (ORAL)

There were no further discussions made by the committee about this class.

Antivertigo/Antiemetic Agents

Recommendations for the PDL are:

- MECLIZINE (AG) (ORAL)
- MECLIZINE (ORAL)
- METOCLOPRAMIDE SOLUTION (ORAL)
- METOCLOPRAMIDE TABLET (ORAL)

- METOCLOPRAMIDE VIAL (INJECTION)
- ONDANSETRON ODT (ORAL)
- ONDANSETRON SOLUTION (ORAL)
- ONDANSETRON TABLETS (ORAL)
- ONDANSETRON VIAL (INTRAVEN)
- PROCHLORPERAZINE (ORAL)
- PROMETHAZINE (RECTAL)
- PROMETHAZINE AMPUL (INJECTION)
- PROMETHAZINE SYRUP (ORAL)
- PROMETHAZINE TABLET (ORAL)
- PROMETHAZINE VIAL (INJECTION)
- SCOPOLAMINE (TRANSDERM)

There were no further discussions made by the committee about this class.

Antifungals, Oral

Recommendations for the PDL are:

- CLOTRIMAZOLE (MUCOUS MEM)
- FLUCONAZOLE SUSPENSION (ORAL)
- FLUCONAZOLE TABLET (ORAL)
- GRISEOFULVIN SUSPENSION (ORAL)
- NYSTATIN SUSPENSION (ORAL)
- NYSTATIN TABLET (ORAL)
- TERBINAFINE (ORAL)

There were no further discussions made by the committee about this class.

Antifungals, Topical

Recommendations for the PDL are:

- CICLOPIROX CREAM (TOPICAL)
- CICLOPIROX SOLUTION (TOPICAL)
- CLOTRIMAZOLE CREAM RX (TOPICAL)
- CLOTRIMAZOLE SOLUTION RX (TOPICAL)
- CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)
- KETOCONAZOLE CREAM (TOPICAL)
- KETOCONAZOLE SHAMPOO (TOPICAL)
- NYSTATIN CREAM (TOPICAL)
- NYSTATIN OINT (TOPICAL)
- NYSTATIN POWDER (TOPICAL)
- NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)
- NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)

There were no further discussions made by the committee about this class.

Antihistamines, First Generation (New)

Recommendations for the PDL are:

- CARBINOXAMINE TABLET (ORAL)
- CHLORPHENIRAMINE TABLET OTC (ORAL)
- CLEMASTINE TABLET (ORAL)
- CYPROHEPTADINE SYRUP (ORAL)
- CYPROHEPTADINE TABLET (ORAL)
- DIPHENHYDRAMINE CAPSULE OTC (ORAL)
- DIPHENHYDRAMINE CHEW OTC (ORAL)
- DIPHENHYDRAMINE LIQUID OTC (ORAL)
- DIPHENHYDRAMINE TABLET OTC (ORAL)
- ED CHLORPED JR SYRUP OTC (ORAL)
- HISTEX PD DROPS OTC (ORAL)
- HYDROXYZINE CAPSULE (AG) (ORAL)
- HYDROXYZINE CAPSULE (ORAL)
- HYDROXYZINE SOLUTION (ORAL)
- HYDROXYZINE TABLET (ORAL)
- PEDIACLEAR PD DROPS OTC (ORAL)
- PEDIACLEAR-8 LIQUID OTC (ORAL)
- TRIPROLIDINE DROPS OTC (ORAL)
- TRIPROLIDINE OTC (ORAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Other

Recommendations for the PDL are:

- AIMOVIG (SUBCUTANEOUS)
- AJOVY (SUBCUTANEOUS)
- AJOVY AUTOINJECTOR (SUBCUTANEOUS)
- AJOVY AUTOINJECTOR 3-PK (SUBCUTANEOUS)
- EMGALITY PEN (SUBCUTANEOUS)
- EMGALITY SYRINGE 120 MG (SUBCUTANEOUS)
- QULIPTA (ORAL)
- UBRELVY (ORAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Triptans

Recommendations for the PDL are:

- RIZATRIPTAN ODT (ORAL)
- RIZATRIPTAN TABLET (ORAL)
- SUMATRIPTAN (AG) (NASAL)

- SUMATRIPTAN (NASAL)
- SUMATRIPTAN (ORAL)
- SUMATRIPTAN VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Antiparasitics, Topical

Recommendations for the PDL are:

- PERMETHRIN CREAM (TOPICAL)
- SPINOSAD (AG) (TOPICAL)

There were no further discussions made by the committee about this class.

Antivirals, Oral

Recommendations for the PDL are:

- ACYCLOVIR CAPSULE (ORAL)
- ACYCLOVIR SUSPENSION (ORAL)
- ACYCLOVIR TABLET (ORAL)
- FAMCICLOVIR (ORAL)
- OSELTAMIVIR CAPSULE (ORAL)
- OSELTAMIVIR SUSPENSION (ORAL)
- VALACYCLOVIR (ORAL)

There were no further discussions made by the committee about this class.

Antivirals, Topical

Recommendations for the PDL are:

- ACYCLOVIR OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Beta Blockers

Recommendations for the PDL are:

- ACEBUTOLOL (ORAL)
- ATENOLOL (ORAL)
- ATENOLOL / CHLORTHALIDONE (ORAL)
- BISOPROLOL (ORAL)
- BISOPROLOL HCTZ (ORAL)
- CARVEDILOL (ORAL)
- HEMANGEOL (ORAL)
- LABETALOL (ORAL)
- METOPROLOL (ORAL)

- METOPROLOL XL (AG) (ORAL)
- METOPROLOL XL (ORAL)
- NADOLOL (ORAL)
- NEBIVOLOL (ORAL)
- PROPRANOLOL ER (AG) (ORAL)
- PROPRANOLOL ER (ORAL)
- PROPRANOLOL SOLUTION (ORAL)
- PROPRANOLOL TABLET (ORAL)
- SOTALOL (ORAL)

There were no further discussions made by the committee about this class.

Bladder Relaxant Preparations

Recommendations for the PDL are:

- FESOTERODINE ER (ORAL)
- OXYBUTYNIN ER (ORAL)
- OXYBUTYNIN SYRUP (ORAL)
- OXYBUTYNIN TABLET (ORAL)
- SOLIFENACIN (ORAL)

There were no further discussions made by the committee about this class.

Bone Resorption Suppression and Related Agents

Recommendations for the PDL are:

- ALENDRONATE TABLETS (ORAL)
- CALCITONIN SALMON (NASAL)
- IBANDRONATE TABLETS (ORAL)
- RALOXIFENE (ORAL)

There were no further discussions made by the committee about this class.

BPH Treatments

Recommendations for the PDL are:

- ALFUZOSIN (ORAL)
- DOXAZOSIN (AG) (ORAL)
- DOXAZOSIN (ORAL)
- DUTASTERIDE (ORAL)
- FINASTERIDE (ORAL)
- TAMSULOSIN (ORAL)
- TERAZOSIN (ORAL)

There were no further discussions made by the committee about this class.

Calcium Channel Blockers

Recommendations for the PDL are:

- AMLODIPINE (ORAL)
- DILTIAZEM CAPSULE ER (ORAL)
- DILTIAZEM TABLET (ORAL)
- FELODIPINE ER (ORAL)
- NIFEDIPINE ER (ORAL)
- NIFEDIPINE IR (ORAL)
- VERAPAMIL TABLET (ORAL)
- VERAPAMIL TABLET ER (ORAL)

There were no further discussions made by the committee about this class.

Cephalosporins and Related Antibiotics

Recommendations for the PDL are:

- AMOXICILLIN/CLAV SUSPENSION (AG) (ORAL)
- AMOXICILLIN/CLAV SUSPENSION (ORAL)
- AMOXICILLIN/CLAV TABLET (AG) (ORAL)
- AMOXICILLIN/CLAV TABLET (ORAL)
- CEFADROXIL CAPSULE (ORAL)
- CEFDINIR CAPSULE (ORAL)
- CEFDINIR SUSPENSION (ORAL)
- CEFPROZIL SUSPENSION (ORAL)
- CEFPROZIL TABLET (ORAL)
- CEFUROXIME TABLET (ORAL)
- CEPHALEXIN CAPSULE (ORAL)
- CEPHALEXIN SUSPENSION (ORAL)

There were no further discussions made by the committee about this class.

Cystic Fibrosis

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Fluoroquinolones, Oral

Recommendations for the PDL are:

- CIPROFLOXACIN TABLET (ORAL)
- LEVOFLOXACIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

GI Motility, Chronic

Recommendations for the PDL are:

- LINZESS (ORAL)
- LUBIPROSTONE (AG) (ORAL)
- LUBIPROSTONE (ORAL)
- RELISTOR SYRINGE (SUBCUTANE.)
- RELISTOR VIAL (SUBCUTANE.)
- TRULANCE (ORAL)

There were no further discussions made by the committee about this class.

Glucagon Agents

Recommendations for the PDL are:

- BAQSIMI (NASAL)
- GLUCAGON EMERGENCY KIT (AMPHASTAR) (INJECTION)
- ZEGALOGUE AUTOINJECTOR (SUBCUTANEOUS)
- ZEGALOGUE SYRINGE (SUBCUTANEOUS)

There were no further discussions made by the committee about this class.

Growth Factors

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Growth Hormone

Recommendations for the PDL are:

- GENOTROPIN CARTRIDGE (INJECTION)
- GENOTROPIN DISP SYRIN (INJECTION)
- NORDITROPIN PEN (INJECTION)

There were no further discussions made by the committee about this class.

H. Pylori Treatment

Recommendations for the PDL are:

- BISMUTH/METRONID/TETRACYCLINE CAPSULE (ORAL)
- TALICIA (ORAL)

There were no further discussions made by the committee about this class.

HAE Treatments

Recommendations for the PDL are:

- HAEGARDA (SUB-Q)
- ICATIBANT (SUBCUT)

There were no further discussions made by the committee about this class.

Hepatitis B Agents (NEW)

Recommendations for the PDL are:

- ADEFOVIR DIPIVOXIL (ORAL)
- ENTECAVIR TABLET (ORAL)
- LAMIVUDINE HBV TABLET (AG) (ORAL)
- LAMIVUDINE HBV TABLET (ORAL)
- VEMLIDY (ORAL)

There were no further discussions made by the committee about this class.

Hepatitis C Agents

Recommendations for the PDL are:

- PEGASYS SYRINGE (SUB-Q)
- PEGASYS VIAL (SUBCUTANE.)
- RIBAVIRIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

Hepatitis C Treatment Course

Recommendations for the PDL:

- SOFOSBUVIR/VELPATASVIR (AG) (ORAL)

There were no further discussions made by the committee about this class.

HIV/AIDS

Recommendations for the PDL are:

- All of the drugs in this class are recommended preferred

There were no further discussions made by the committee about this class.

Hypoglycemics, Alpha-Glucosidase Inhibitors

Recommendations for the PDL are:

- ACARBOSE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Incretin Mimetics/Enhancers

Recommendations for the PDL are:

- JANUMET (ORAL)
- JANUMET XR (ORAL)
- JANUVIA (ORAL)
- JENTADUETO (ORAL)
- OZEMPIC (SUBCUTANE.)
- RYBELSUS (ORAL)
- TRADJENTA (ORAL)
- TRULICITY (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Hypoglycemics, Insulin and Related Agents

Recommendations for the PDL are:

- HUMULIN 500 U/M PEN (SUBCUTANE.)
- HUMULIN 500 U/M VIAL (SUBCUTANE.)
- HUMULIN 70/30 PEN OTC (SUBCUTANE.)
- HUMULIN 70/30 VIAL OTC (SUBCUTANE.)
- HUMULIN VIAL OTC (SUBCUTANE.)
- INSULIN ASPART CARTRIDGE (AG) (SUBCUTANE.)
- INSULIN ASPART PEN (AG) (SUBCUTANE.)
- INSULIN ASPART VIAL (AG) (SUBCUTANE.)
- INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS)
- INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANE.)
- INSULIN GLARGINE PEN (SUBCUTANE.)
- INSULIN GLARGINE VIAL (SUBCUTANE.)
- INSULIN LISPRO JUNIOR KWIKPEN (AG) (SUBCUTANE.)
- INSULIN LISPRO PEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS)
- LANTUS SOLOSTAR PEN (SUBCUTANE.)
- LANTUS VIAL (SUBCUTANE.)
- APIDRA SOLOSTAR PEN (SUBCUTANE.)
- APIDRA VIAL (SUBCUTANE.)
- HUMALOG CARTRIDGE (SUBCUTANE.)
- HUMALOG JUNIOR KWIKPEN (SUBCUTANE.)
- HUMALOG MIX PEN (SUBCUTANE.)
- HUMALOG MIX VIAL (SUBCUTANE.)
- HUMALOG PEN (SUBCUTANE.)
- HUMALOG VIAL (SUBCUTANE.)
- NOVOLOG CARTRIDGE (SUBCUTANE.)
- NOVOLOG MIX PEN (SUBCUTANE.)
- NOVOLOG MIX VIAL (SUBCUTANE.)

- NOVOLOG PEN (SUBCUTANE.)
- NOVOLOG VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Hypoglycemics, Meglitinides

Recommendations for the PDL are:

- NATEGLINIDE (ORAL)
- REPAGLINIDE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Metformins

Recommendations for the PDL are:

- GLIPIZIDE-METFORMIN (ORAL)
- GLYBURIDE-METFORMIN (ORAL)
- METFORMIN (ORAL)
- METFORMIN ER (GLUCOPHAGE XR) (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, SGLT2

Recommendations for the PDL are:

- DAPAGLIFLOZIN (AG) (ORAL)
- DAPAGLIFLOZIN-METFORMIN ER (AG) (ORAL)
- JARDIANCE (ORAL)
- SYNJARDY (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Sulfonylureas

Recommendations for the PDL are:

- GLIMEPIRIDE (ORAL)
- GLIPIZIDE (ORAL)
- GLIPIZIDE ER (ORAL)
- GLYBURIDE (ORAL)
- GLYBURIDE MICRONIZED (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, TZD

Recommendations for the PDL are:

- PIOGLITAZONE (ORAL)

There were no further discussions made by the committee about this class.

Immunosuppressives, Oral

Recommendations for the PDL are:

- AZATHIOPRINE (ORAL)
- CYCLOSPORINE SOFTGEL (ORAL)
- CYCLOSPORINE, MODIFIED CAPSULE (ORAL)
- MYCOPHENOLATE MOFETIL CAPSULE (ORAL)
- MYCOPHENOLATE MOFETIL TABLET (ORAL)
- MYCOPHENOLIC ACID (ORAL)
- RAPAMUNE TABLET (ORAL)
- SIROLIMUS SOLUTION (ORAL)
- SIROLIMUS TABLET (AG) (ORAL)
- SIROLIMUS TABLET (ORAL)
- TACROLIMUS (ORAL)

There were no further discussions made by the committee about this class.

Lincosamides/Oxazolidinones/Streptogramins

Recommendations for the PDL are:

- CLINDAMYCIN CAPSULES (ORAL)
- CLINDAMYCIN PALMITATE SOLUTION (ORAL)
- LINEZOLID TABLET (AG) (ORAL)
- LINEZOLID TABLET (ORAL)

There were no further discussions made by the committee about this class.

Lipotropics, Other

Recommendations for the PDL are:

- CHOLESTYRAMINE/ASPARTAME (ORAL)
- CHOLESTYRAMINE/SUCROSE (ORAL)
- COLESEVELAM (AG) (ORAL)
- COLESEVELAM (ORAL)
- COLESTIPOL GRANULES (ORAL)
- COLESTIPOL TABLET (ORAL)
- EZETIMIBE (ORAL)
- FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)
- FENOFIBRATE TABLET (LOFIBRA) (ORAL)
- FENOFIBRATE TABLET (TRICOR) (ORAL)
- GEMFIBROZIL (ORAL)

- ICOSAPENT ETHYL (ORAL)
- NIACIN ER (ORAL)
- OMEGA-3 ACID ETHYL ESTERS (ORAL)
- REPATHA PUSHTRONEX (SUBCUTANEOUS)
- REPATHA SURECLICK (SUBCUTANEOUS)
- REPATHA SYRINGE (SUBCUTANEOUS)

There were no further discussions made by the committee about this class.

Lipotropics, Statins

Recommendations for the PDL are:

- ATORVASTATIN (ORAL)
- EZETIMIBE-SIMVASTATIN (ORAL)
- LOVASTATIN (ORAL)
- PRAVASTATIN (ORAL)
- ROSUVASTATIN (ORAL)
- SIMVASTATIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

Macrolides/Ketolides

Recommendations for the PDL are:

- AZITHROMYCIN PACKET (AG) (ORAL)
- AZITHROMYCIN SUSPENSION (ORAL)
- AZITHROMYCIN TABLET (ORAL)
- CLARITHROMYCIN TABLET (ORAL)
- ERYTHROMYCIN BASE TABLET DR (ORAL)

There were no further discussions made by the committee about this class.

Multiple Sclerosis Agents

Recommendations for the PDL are:

- AVONEX (INTRAMUSC.)
- AVONEX PEN (INTRAMUSC.)
- BETASERON KIT (SUBCUTANE.)
- DALFAMPRIDINE ER (ORAL)
- DIMETHYL FUMARATE DR (ORAL)
- DIMETHYL FUMARATE DR STARTER PACK (ORAL)
- FINGOLIMOD (ORAL)
- GLATIRAMER 20 MG/ML (SUBCUTANE.)
- GLATIRAMER 40 MG/ML (SUBCUTANE.)
- KESIMPTA (SUBCUTANE.)
- TERIFLUNOMIDE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Multivitamins (New)

Recommendations for the PDL are:

- BACMIN (ORAL)
- VIT 3 (ORAL)
- STROVITE ONE (ORAL)

There were no further discussions made by the committee about this class.

Nitrofurantoin Derivatives

Recommendations for the PDL are:

- NITROFURANTOIN MACROCRYSTALS CAPSULES (AG) (ORAL)
- NITROFURANTOIN MACROCRYSTALS CAPSULES (ORAL)
- NITROFURANTOIN MONO-MACRO CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Opiate Dependence Treatments

Recommendations for the PDL are:

- BRIXADI MONTHLY (SUBCUTANEOUS)
- BRIXADI WEEKLY (SUBCUTANEOUS)
- BUPRENORPHINE HCL (SUBLINGUAL)
- BUPRENORPHINE/NALOXONE FILM (SUBLINGUAL)
- BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)
- NALTREXONE (ORAL)
- KLOXXADO SPRAY (NASAL)
- NALOXONE SPRAY (AG) (NASAL)
- NALOXONE SPRAY (NASAL)
- NALOXONE SPRAY OTC (NASAL)
- NALOXONE SYRINGE (INJECTION)
- NALOXONE VIAL (INJECTION)
- NARCAN SPRAY OTC (NASAL)
- SUBLOCADE (SUBCUTANEOUS)
- VIVITROL (INTRAMUSC)
- ZUBSOLV (SUBLINGUAL)

There were no further discussions made by the committee about this class.

PAH Agents, Oral and Inhaled

Recommendations for the PDL are:

- AMBRISENTAN (ORAL)
- BOSENTAN TABLET (ORAL)

- SILDENAFIL SUSPENSION (ORAL)
- SILDENAFIL TABLET (ORAL)
- TADALAFIL (ADCIRCA) (ORAL)

There were no further discussions made by the committee about this class.

Pancreatic Enzymes

Recommendations for the PDL are:

- CREON (ORAL)
- ZENPEP (ORAL)

There were no further discussions made by the committee about this class.

Pediatric Vitamin Preparations

Recommendations for the PDL are:

- FLUORIDE/VITAMINS A, C, AND D DROPS (ORAL)
- MULTIVITAMINS WITH FLUORIDE DROPS (ORAL)
- MULTIVITS WITH IRON & FLUORIDE DROPS (ORAL)
- PEDI MVI NO.17 WITH FLUORIDE CHEW (ORAL)

There were no further discussions made by the committee about this class.

Phosphate Binders

Recommendations for the PDL are:

- CALCIUM ACETATE CAPSULE (ORAL)
- SEVELAMER CARBONATE TABLET (AG) (ORAL)
- SEVELAMER CARBONATE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Pituitary Suppressive Agents, LHRH

Recommendations for the PDL are:

- FENSOLVI 6-MONTH (SUBCUTANEOUS)
- LEUPROLIDE ACETATE (SUBCUTANEOUS)
- LUPRON DEPOT 1MO KIT (INJECTION)
- LUPRON DEPOT 3MO KIT (INJECTION)
- LUPRON DEPOT 4MO KIT (INJECTION)
- LUPRON DEPOT 6MO KIT (INJECTION)
- SYNAREL (NASAL)

There were no further discussions made by the committee about this class.

Platelet Aggregation Inhibitors

Recommendations for the PDL are:

- ASPIRIN/DIPYRIDAMOLE (ORAL)
- BRILINTA (ORAL)
- CLOPIDOGREL (ORAL)
- DIPYRIDAMOLE (ORAL)
- PRASUGREL (ORAL)

There were no further discussions made by the committee about this class.

Potassium Binders

Recommendations for the PDL are:

- LOKELMA (ORAL)
- SODIUM POLYSTYRENE SULFONATE (ORAL)

There were no further discussions made by the committee about this class.

Prenatal Vitamins (NEW)

Recommendations for the PDL are:

- COMPLETENATE CHEW TABLET (ORAL)
- ENBRACE HR (ORAL)
- FE C/FA (ORAL)
- NESTABS DHA (ORAL)
- PNV COMBO#47/IRON/FA #1/DHA (ORAL)
- PNV NO.118/IRON FUMARATE/FA CHEW TABLET (ORAL)
- PNV NO.15/IRON FUM & PS CMP/FA (ORAL)
- PNV WITH CA,NO.72/IRON/FA (ORAL)
- PNV#16/IRON FUM & PS/FA/OM-3 (ORAL)
- PNV119/IRON FUMARATE/FA/DSS TABLET (ORAL)
- PNV2/IRON B-G SUC-P/FA/OMEGA-3 (ORAL)
- PRENATAL VIT #76/IRON,CARB/FA (ORAL)
- SELECT-OB + DHA (ORAL)
- TRICARE (ORAL)
- TRINATAL RX 1 (ORAL)
- VITAFOL FE+ (ORAL)
- VITAFOL TAB CHEW (ORAL)
- VITAFOL ULTRA (ORAL)
- VITAFOL-OB (ORAL)
- VITAFOL-OB+DHA (ORAL)
- VITAFOL-ONE (ORAL)

There were no further discussions made by the committee about this class.

Proton Pump Inhibitors

Recommendations for the PDL are:

- ESOMEPRAZOLE SUSPENSION (ORAL)

- LANSOPRAZOLE CAPSULES (ORAL)
- LANSOPRAZOLE SOLUTAB (ORAL)
- OMEPRAZOLE (ORAL)
- PANTOPRAZOLE (ORAL)

There were no further discussions made by the committee about this class.

Sinus Node Inhibitors

Recommendations for the PDL are:

- IVABRADINE TABLET (ORAL)

There were no further discussions made by the committee about this class.

Skeletal Muscle Relaxants

Recommendations for the PDL are:

- BACLOFEN (ORAL)
- CYCLOBENZAPRINE (ORAL)
- METHOCARBAMOL (ORAL)
- TIZANIDINE TABLETS (ORAL)

There were no further discussions made by the committee about this class.

Tetracyclines

Recommendations for the PDL are:

- DOXYCYCLINE HYCLATE CAPSULE (ORAL)
- DOXYCYCLINE HYCLATE TABLET (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE TABLET (ORAL)
- MINOCYCLINE CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Ulcerative Colitis Agents

Recommendations for the PDL are:

- BALSALAZIDE (ORAL)
- MESALAMINE (CANASA) (AG) (RECTAL)
- MESALAMINE (CANASA) (RECTAL)
- MESALAMINE ER (APRISO) (AG) (ORAL)
- MESALAMINE ER (APRISO) (ORAL)
- SULFASALAZINE (AG) (ORAL)

- SULFASALAZINE (ORAL)
- SULFASALAZINE DR (AG) (ORAL)

There were no further discussions made by the committee about this class.

Uterine Disorder Treatments

Recommendations for the PDL are:

- MYFEMBREE (ORAL)
- ORIAHNN (ORAL)
- ORILISSA (ORAL)

There were no further discussions made by the committee about this class.

Vasodilators, Coronary

Recommendations for the PDL are:

- ISOSORBIDE DINIT/HYDRALAZINE TABLET (AG) (ORAL)
- ISOSORBIDE DINITRATE (AG) (ORAL)
- ISOSORBIDE DINITRATE (ORAL)
- ISOSORBIDE DINITRATE/HYDRALAZINE (ORAL)
- ISOSORBIDE MONONITRATE (ORAL)
- ISOSORBIDE MONONITRATE SR (ORAL)
- NITRO-BID OINT. (TRANSDERM)
- NITROGLYCERIN (AG) (SUBLINGUAL)
- NITROGLYCERIN (AG) (TRANSDERM)
- NITROGLYCERIN (SUBLINGUAL)
- NITROGLYCERIN (TRANSDERM)

There were no further discussions made by the committee about this class.

Single Drug Reviews

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Aaron	Bristol-Myers Squibb	Cobenfy
Kirk Latibeaudiere	Teva	Selarsdi
Carla McSpadden	Galderma	Nemluvio
Taha Khan	Vertex	Journavx
Christy Schaffer	Springworks Therapeutic	Gomekli
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed, and their recommendations are:

Antiparkinson's Agents

Recommendations for the PDL are:

- ONAPGO (SUBCUTANEOUS) - recommended NPD
- VYALEV VIAL (SUBCUTANEOUS) - recommended NPD

Antipsychotics

Recommendations for the PDL are:

- COBENFY (ORAL) – recommended NPD
- COBENFY STARTER PACK (ORAL) – recommended NPD
- ERZOFRI (INTRAMUSC) – recommended NPD
- OPIPZA FILM (ORAL) – recommended NPD

Cytokine and CAM Antagonists

Recommendations for the PDL are:

- OTULFI SYRINGE (SUBCUTANEOUS) – recommended NPD
- OTULFI VIAL (INTRAVENOUS) – recommended NPD
- PYZCHIVA SYRINGE (SUBCUTANEOUS) – recommended NPD
- PYZCHIVA VIAL (INTRAVENOUS) – recommended NPD
- SELARSDI SYRINGE (SUBCUTANE.) – recommended NPD
- SELARSDI VIAL (INTRAVENOUS) – recommended NPD
- SIMLANDI KIT (INJECTION) (CF) 100 MG/ML– recommended NPD
- STEQEYMA SYRINGE (SUBCUTANE.) – recommended NPD
- STEQEYMA VIAL (INJECTION) – recommended NPD
- TREMFYA PEN (SUBCUTANE.) – recommended NPD
- TREMFYA VIAL (INTRAVENOUS) – recommended NPD
- YESINTEK SYRINGE (SUBCUTANE.) – recommended NPD
- YESINTEK VIAL (INJECTION) – recommended NPD

Epinephrine, Self-Injected

Recommendations for the PDL are:

- NEFFY SPRAY (NASAL) – recommended NPD

Hemophilia Treatment

Recommendations for the PDL are:

- ALHEMO PEN (SUBCUTAN.) – recommended NPD
- HYMPAVZI PEN (SUBCUTANE.) – recommended NPD

Immunomodulators, Atopic Dermatitis

Recommendations for the PDL are:

- EBGLYSS PEN (SUBCUTANEOUS) – recommended NPD
- EBGLYSS SYRINGE (SUBCUTANEOUS) – recommended NPD
- NEMLUVIO PEN (SUBCUTANEOUS) – recommended NPD

Neuropathic Pain and Select Agents

Recommendations for the PDL are:

- GABARONE TABLET (ORAL) – recommended NPD
- JOURNAVX TABLET (ORAL) – recommended NPD
- LYRICA SOLUTION (ORAL) – recommended NPD

NSAIDs

Recommendations for the PDL are:

- DOLOBID (ORAL) – recommended NPD

Oncology, Oral – Breast

Recommendations for the PDL are:

- ITOVEBI (ORAL) – recommended NPD

Oncology, Oral – Hematologic

Recommendations for the PDL are:

- DANZITEN TABLET (ORAL) – recommended NPD
- IMKELDI SOLUTION (ORAL) – recommended NPD

Oncology, Oral- Other

Recommendations for the PDL are:

- ROMVIMZA (ORAL) – recommended NPD

Oncology, Oral- Skin

Recommendations for the PDL are:

- GOMEKLI (ORAL) – recommended NPD
- GOMEKLI TAB SUSP (ORAL) – recommended NPD

Sickle Cell Anemia

Recommendations for the PDL are:

- XROMI SOLUTION (ORAL) – recommended NPD

Proposed Therapeutic Classes to be Reviewed at Next Meeting



The committee members were shown the list of therapeutic classes that will be reviewed on the fall 2025 meeting.

Next Meeting Date

The proposed date for the next P&T committee meeting is 11/05/2025 or 11/07/2025.

Adjournment

The meeting adjourned at or about 10:28 am CT.